Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ervant J. Maksabedian Hernandez, Marlon Graf, Alexandria Portelli & Jason Shafrin. (2022) Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulators. Journal of Medical Economics 25:1, pages 1118-1126.
Read now
Read now
Allan Gibofsky, Martha Skup, Manish Mittal, Scott J. Johnson, Matthew Davis, Jingdong Chao & David T. Rubin. (2017) Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Current Medical Research and Opinion 33:11, pages 1945-1953.
Read now
Read now
Joerg Mahlich & Rosarin Sruamsiri. (2017) Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Current Medical Research and Opinion 33:1, pages 101-107.
Read now
Read now
Articles from other publishers (27)
Patryk J. Drobinski, Anne C. Bay-Jensen, Morten A. Karsdal, Samra Sardar & Anne S. Siebuhr. (2021) Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study. Arthritis Research & Therapy 23:1.
Crossref
Crossref
Vibeke Strand, Joao Goncalves & John D. Isaacs. (2020) Immunogenicity of biologic agents in rheumatology. Nature Reviews Rheumatology 17:2, pages 81-97.
Crossref
Crossref
Alberto Migliore, Giuseppe Pompilio, Davide Integlia, Joe Zhuo & Evo Alemao. (2021)
Cycling of tumor necrosis factor inhibitors
versus
switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis
. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110026.
Crossref
Crossref
Francisco J. Blanco, Esteban Rubio-Romero, Raimon Sanmartí, César Díaz-Torné, Pablo Talavera, Jochen Dunkel & Esperanza Naredo. (2020) Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure. Reumatología Clínica (English Edition) 16:5, pages 345-352.
Crossref
Crossref
Francisco J. Blanco, Esteban Rubio-Romero, Raimon Sanmartí, César Díaz-Torné, Pablo Talavera, Jochen Dunkel & Esperanza Naredo. (2020) Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure. Reumatología Clínica 16:5, pages 345-352.
Crossref
Crossref
Rishi J. Desai, Seoyoung C. Kim, Jeffrey R. Curtis, Jaclyn L.F. Bosco, Bernadette Eichelberger, Charles E. Barr, Catherine M. Lockhart, Brian D. Bradbury, Jerry Clewell, Hillel P. Cohen & Joshua J. Gagne. (2019) Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiology and Drug Safety 29:7, pages 757-769.
Crossref
Crossref
Roy Fleischmann, Vipul Jairath, Eduardo Mysler, Dave Nicholls & Paul Declerck. (2020) Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?. Rheumatology and Therapy 7:1, pages 35-64.
Crossref
Crossref
Noemi MuszbekClare Proudfoot, Marie FournierChieh-I ChenAndreas KuznikZsofia KissPeter Gal & Kaleb Michaud. (2019) Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1268-1280.
Crossref
Crossref
Ashvini Reddy, Fauziyya Muhammad & Darren J. Lee. 2019. Advances in the Diagnosis and Management of Uveitis. Advances in the Diagnosis and Management of Uveitis.
Juliana Miranda de Lucena Valim, Fernanda Gomes Gonçalves Chaer, Fernanda D'Oliveira Guimarães da Silveira, Verônica Palmiro da Silva e Lima & Branca Dias Batista de Souza. (2019) Switching of biological therapies in Brazilian patients with rheumatoid arthritis. Future Science OA 5:1.
Crossref
Crossref
Syed Numan & Freddy Faccin. (2018) Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. Advances in Therapy 35:9, pages 1295-1332.
Crossref
Crossref
Christoph Garbers, Sylvia Heink, Thomas Korn & Stefan Rose-John. (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nature Reviews Drug Discovery 17:6, pages 395-412.
Crossref
Crossref
Santiago Muñoz-Fernández, María Sagrario Bustabad Reyes, Jaime Calvo Alén, Manuel Castaño Sánchez, Eugenio Chamizo Carmona, Héctor Corominas, Nagore Fernández-Llanio Comella, María Cristina Hidalgo Calleja, José Javier Pérez Venegas, José Manuel Rodríguez Heredia, Susana María Romero Yuste & Virginia Ruiz-Esquide Torino. (2018) Biologic Disease-modifying Antirheumatic Drug Attributes in the First Lines of Treatment of Rheumatoid Arthritis. 2015 ACORDAR Project. Reumatología Clínica (English Edition) 14:2, pages 90-96.
Crossref
Crossref
Santiago Muñoz-Fernández, María Sagrario Bustabad Reyes, Jaime Calvo Alén, Manuel Castaño Sánchez, Eugenio Chamizo Carmona, Héctor Corominas, Nagore Fernández-Llanio Comella, María Cristina Hidalgo Calleja, José Javier Pérez Venegas, José Manuel Rodríguez Heredia, Susana María Romero Yuste & Virginia Ruiz-Esquide Torino. (2018) Atributos del fármaco antirreumático modificador de la enfermedad biológico en las primeras líneas de tratamiento de la artritis reumatoide. Proyecto ACORDAR 2015. Reumatología Clínica 14:2, pages 90-96.
Crossref
Crossref
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi & Seoyoung C. Kim. (2017) Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. Arthritis Research & Therapy 19:1.
Crossref
Crossref
Vibeke Strand, Paul Miller, Setareh A. Williams, Katherine Saunders, Shannon Grant & Joel Kremer. (2017) Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. Rheumatology and Therapy 4:2, pages 489-502.
Crossref
Crossref
Mohammed I. Aladul, Raymond W. Fitzpatrick & Stephen R. Chapman. (2017) Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs 31:6, pages 533-544.
Crossref
Crossref
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik & Wenhui Wei. (2017) Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA. Advances in Therapy 34:11, pages 2422-2435.
Crossref
Crossref
Nanxin Li, Keith A. Betts, Andrew J. Messali, Martha Skup & Vishvas Garg. (2017) Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany. Clinical Therapeutics 39:8, pages 1618-1627.
Crossref
Crossref
Wenhui Wei, Keith Knapp, Li Wang, Chieh-I Chen, Gary L. Craig, Karen Ferguson & Sergio Schwartzman. (2017) Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy. Advances in Therapy 34:8, pages 1936-1952.
Crossref
Crossref
Corrado Blandizzi, Pier Luigi Meroni & Giovanni Lapadula. (2017) Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. Clinical Therapeutics 39:5, pages 1026-1039.
Crossref
Crossref
Lucy Smithers. (2016) Biologic Therapies: Clinical Practice in a Changing Environment. EMJ Dermatology, pages 38-44.
Crossref
Crossref
Amir Hashemi-Meshkini, Shekoufeh Nikfar, Elizabeth Glaser, Ahmadreza Jamshidi & Seyed Alireza Hosseini. (2016) Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. Value in Health Regional Issues 9, pages 42-48.
Crossref
Crossref
Frederik C. J. Bester, Fredricka J. Bosch & Barend J. Jansen van Rensburg. (2016) The specialist physician’s approach to rheumatoid arthritis in South Africa. The Korean Journal of Internal Medicine 31:2, pages 219-236.
Crossref
Crossref
Vanessa Lane. (2015) Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment. EMJ Gastroenterology, pages 50-57.
Crossref
Crossref
Morten A. Karsdal, Anne-Christine Bay-Jensen, Kim Henriksen, Claus Christiansen, Harry K. Genant, Chris Chamberlain & Adam Platt. (2014) Rheumatoid Arthritis: A Case for Personalized Health Care?. Arthritis Care & Research 66:9, pages 1273-1280.
Crossref
Crossref
M.A. Karsdal, C. Christiansen, C. Ladel, K. Henriksen, V.B. Kraus & A.C. Bay-Jensen. (2014) Osteoarthritis – a case for personalized health care?. Osteoarthritis and Cartilage 22:1, pages 7-16.
Crossref
Crossref